These results deliver unequivocal and compelling evidence that MZT2B expression is markedly and persistently elevated at both the mRNA and protein levels in human NSCLC clinical specimens and representative cell models, demonstrating a consistent pattern when compared to their non-malignant counterparts. This evidence concerns the gene MZT2B and non-small cell lung carcinoma.